STTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Shattuck Labs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$5.37−0.05 (-0.92%)

Close on Oct 19, 2026

Market cap: $696.91M
P/E (TTM): –
Dividend yield: –

Shattuck Labs, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Depreciation & Amortization	3.70	3.80	4.00	3.10	1.40	0.60	0.50
Stock-Based Compensation	7.00	9.55	6.94	6.46	5.47	1.27	0.46
Change in Accounts Payable	-0.32	0.83	-5.63	-2.84	7.87	-1.75	1.00
Change in Unearned Revenue	–	–	0.34	0	-29	6.57	-2.97
Operating Cash Flow	-40	-61	-81	-94	-57	-34	-21
Capital Expenditures	-0.07	-0.06	-0.41	-12	-7.93	-0.73	-0.47
Sale of Property, Plant & Equipment	–	–	0	0.10	0	–	–
Purchase of Investments	-43	-94	-80	-132	-204	-183	-44
Investing Cash Flow	-7.89	-8.51	111	49	-10	-146	-3.59
Stock Issued	44	–	48	0	–	–	–
Taxes Paid on Share-Based Awards	-0.07	-0.45	-0.05	0	–	–	–
Financing Cash Flow	45	0.79	49	0.17	1.93	331	-0.06
Net Change in Cash	-3.20	-68	78	-45	-66	151	-25
Free Cash Flow	-40	-61	-82	-106	-65	-34	-21

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -5578.7%
Net margin: -5256.8%
Return on equity, FY2025: -60.3%

Financial strength

Current ratio: 27.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 818.8%

Valuation

P/E ratio: –
Price to sales: 696.91
Price to book: 3.30
Dividend yield: –